跳至主要内容
临床试验/NCT02263378
NCT02263378已完成不适用

Ellagic Acid and Annona Muricata May Modulate the Immune Response to High Risk HPV Infection. A Randomized, Controlled Trial.

University of Messina0 个研究点目标入组 60 人开始时间: 2014年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
60
主要终点
variation of onco suppressor protein expression from basal values. The expression variations are represented by the different percentage of positive cells

研究概览

简要总结

The purpose of this study is to evaluate whether a supplement in which ellagic acid plus annona muricata are combined, may modulate the immune response to high risk HPV infection. Sixty women will be enrolled in a randomized, controlled study, having a histological diagnosis of L-SIL correlated with high rish HPV types infection. Main outcome measure is the activation of onco suppressor protein by the supplement and secondary outcome is the clearance of HPV infection in the treated group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • women with high risk HPV infection
  • histological diagnosis of L-SIL

排除标准

  • women with no high risk HPV infection
  • women without histological diagnosis of L-SIL

研究组 & 干预措施

supplement

Experimental

干预措施: ellagic acid + annona muricata (Drug)

not intervention

Placebo Comparator

干预措施: ellagic acid + annona muricata (Drug)

结局指标

主要结局

variation of onco suppressor protein expression from basal values. The expression variations are represented by the different percentage of positive cells

时间窗: 6 months

次要结局

  • clearance of the HPV infection(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rosario D'anna

associate professor

University of Messina

相似试验